


Jennerex is a clinical stage company focused on the discovery and the development of targeted cancer therapeutics. Jennerex intends to enter into both development and commercialization alliances with partners to bring the first-in-class cancer therapeutics to patients world-wide.
Jennerex has proprietary technology platforms which can generate highly targeted, oncolytic virus agents for the effective treatment of cancers. Jennerex is continually reviewing new discoveries and breakthrough technologies for in-license and collaborations opportunities.
We seek to develop value-creating corporate alliances with commercial and academic partners. These alliances will be based on cutting-edge science, innovation and complementary attributes and skill sets. We will explore alliances in the areas of product discovery, development, manufacturing and commercialization in specific geographic regions world-wide.
We currently have a product development and licensing agreement for JX-594 with Green Cross (Seoul, S. Korea) for the Korean market. Together we are focused on the development and eventual commercialization of JX-594 for liver cancers and other cancer indications in the Korean market. Green Cross is a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products.